Use of parathyroid hormone in hypoparathyroidism.
Hypoparathyroidism is a disorder characterized by hypocalcemia, deficient PTH, and abnormal bone remodeling. Standard treatment of hypoparathyroidism consists of oral calcium and vitamin D supplementation. However, maintaining serum calcium levels can be a challenge. In addition, concerns exist regarding hypercalciuria and ectopic calcifications that can be associated with such treatment. Hypoparathyroidism is the only classic endocrine deficiency disease for which the missing hormone, PTH, is not yet an approved treatment. This review focuses on the use of PTH in the treatment of hypoparathyroidism, in the form of teriparatide [PTH(1-34)] and the full-length molecule, PTH(1-84). Studies in hypoparathyroid subjects demonstrate that PTH(1-34) and PTH(1-84) lower or abolish supplemental calcium and vitamin D requirements as well as increase markers of bone turnover. Densitometric and histomorphometric studies in some subjects treated with PTH(1- 34) and PTH(1-84) show an improvement in bone-remodeling dynamics and return of bone metabolism toward normal levels. Given the chronic nature of hypoparathyroidism, and the expectation that PTH will be used for extended periods of time in hypoparathyroidism, further studies are needed to determine the long-term safety of PTH therapy in this population.
Department of Medicine, Division of Endocrinology, College of Physicians & Surgeons, Columbia University, New York, NY, USA.
N E
NE
Cusano
M R
MR
Rubin
D
D
Irani
J
J
Sliney
J P
JP
Bilezikian
D000293:Adolescent; D000328:Adult; D000368:Aged; D016723:Bone Remodeling / Q000187:drug effects; D002118:Calcium / Q000627:therapeutic use; D002648:Child; D006801:Humans; D007011:Hypoparathyroidism / Q000188:drug therapy*; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000008:administration & dosage*; D019379:Teriparatide / Q000627:therapeutic use*; D014807:Vitamin D / Q000627:therapeutic use
D010281:Parathyroid Hormone; D019379:Teriparatide; D014807:Vitamin D; D002118:Calcium